

# “Prevention is better than cure” — exploration in cancer



Dr Biswa P Das Purkayastha  
Associate Professor  
Narayana Medical College  
Nellore, A. P.



# Education

Master of Science

July 2003 - June 2005



**Jiwaji University**

**Molecular & Human Genetics**

Gwalior (Madhya Pradesh), India

Doctoral research

(Molecular & Human Genetics)

January 2006 - October 2012



**Study on the transcription factor, BRN3A, in etiology of uterine cervix cancer**

Varanasi (Uttar Pradesh), India



## Postdoctoral Research Experience

(Academic); March, 2015 - February, 2017




### Title: Molecular mechanism of metastasis & chemoresistance in aggressive lung cancer

#### Novel Research Finding/s:

- Development of a robust lung cancer metastasis animal model
- Molecular mechanism of metastasis & chemoresistance in aggressive lung cancer

#### Publication/s: (Total-2)

- A spontaneous metastasis model reveals the significance of claudin-9 overexpression in lung cancer metastasis, *Clinical & Experimental Metastasis*, 33(3), 263-275, 2016
- Hypertension exaggerates renovascular resistance via miR-122 associated stress response in aging, *Journal of Hypertension*, 36(11), 2226-2236, 2018





## Postdoctoral Research Experience

(Academic); February 2017 - January, 2020






### Title: Understand the molecular genetics involved in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC)

#### Novel Research Finding/s:

- Discovery of a novel transcript variant ( $COL10A1^{Var}$ ) of  $COL10A1$  gene, and its identification as molecular biomarker for esophageal adenocarcinoma (EAC)
- Discover the familial basis of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC)

#### Publication/s: (Total-2)

- Genome-scale analysis identifies novel transcript variants in esophageal adenocarcinoma, *Cellular & Molecular Gastroenterology & Hepatology*, 2020
- Familial basis of BE and EAC ( *Manuscript under preparation* )



## Industrial research experience

January 2020 - May 2021



Gurgaon (HR), INDIA

### **Development of 3-D mammalian cell-culture model using a patented technology**

#### Novel Research Finding/s:

- Worked as scientific strategist in development of a patented 3D Cell-culture technology
- Also, successfully performed animal trial of Covid-19 vaccine, which would be the first oral Covid-19 vaccine

#### Publication/s: (Total-3)

- A Baru, S Sharma, **BP Das Purkayastha**, *et.al.*, (**Under review**). AXTEX-4D™: A novel 3D *ex vivo* platform for preclinical investigations of immunotherapy agents
- A Baru, S Mazumdar, P Kundu, S Sharma, **BP Das Purkayastha**, *et.al.*, (**Under review**). Recapitulating tumor microenvironment using preclinical 3D tissueoids model for accelerating cancer research and drug screening
- S Mazumdar, R rastogi, A Sundale, K Arora, N M Arora, **BP Das Purkayastha**, *et.al.*, (**Under review**). PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2



# Doctor of Philosophy (Molecular & Human Genetics) January 2006 - October 2012



**Title: Study on the transcription factor, BRN3A, in etiology of uterine cervix cancer**

## Novel Research Finding/s:

- Homeodomain transcription factor, BRN3A, is one of the key component in uterine cervix cancer and specifically in HPV-induced ones
- Discovery of a novel snp 60163379 A>G (Accession Number: ss289117722), which is modulating uterine cervix *BRN3A* expression in response to progesterone

**NCBI dbSNP Short Genetic Variations**

Search for SNP on NCBI Reference Assembly

Submitted SNP(ss) Details: ss289117722

Submitter: [BPDASIKROYCYTOZOQBHU](#)

Handle: [BRN3A-A60163379G](#)

Submitter SNP ID: BRN3A-A60163379G

RefSNP(rs#): [rs1555813](#)

Submitted Batch ID: [BRN3Aenhc](#)

Submitted Date: Dec 27, 2010

Publication: [\[1\]](#) BRN3A as the key component in HPV-induced cervical cancer

First entry to dbSNP: Dec 27 2010 12:00:00:000AM

Assay: Species Homo sapiens

Molecular Type: Genomic

Method: [BRN3AENHC-A60163379G](#)

Ascertainment Samplesize: 76

Population: [BRN3Aenhc](#)

Resource Links

Submitted Gene Name: N.D.

Submitted Gene ID: N.D.

Submitted SNP Synonyms: N.D.

Submitted linkout: N.D.

Submission report: [view](#)

Allele

Observed Allele: A/G

Ancestral Allele: N.D.

Allele Origin: NA

SNP Class: SNV


CpG Code: N.D.

## *Prologue*

- In a normal human body, ten million cells have been observed to be in the stage of division in every minute. Cell division occurs with utmost precision and may be accompanied by specialized development/differentiation
- Nevertheless, uncontrolled cell- division leads to the formation of mass of cells, which has been coined as 'tumour', and may finally culminate into one of the most deadly diseases haunting mankind, 'malignant tumour' or 'cancer'
- The term, 'cancer', was coined by the 'Father of Medicine', Hippocrates (400 BC), which originated from the term, 'carcinos' and 'carcinoma', a Latin word meaning 'crab'.



## NORMAL CELLS



## CANCEROUS CELLS



Many cells that  
continue to grow  
and divide

Variations in  
size and shapes  
of cells

Nucleus that  
is larger and  
darker than  
normal

Abnormal  
number of  
chromosomes  
arranged in a  
disorganized  
fashion


Cluster of  
cells without a  
boundry



# **Study on the transcription factor, BRN3A, in etiology of uterine cervix cancer**



Cervix (Latin *cervix uteri*, meaning "neck of the womb") is the narrow end of the uterus that opens into the upper part of the vagina and serves as the birth canal




There are two epithelial linings in the uterine cervix

# Squamous epithelium (Ectocervix)

# Columnar epithelium (Endocervix)

The junction of these two epithelial linings, known as squamo-columnar junction, is the site of initiation of transformation and hence, this region is known as ‘transformation zone’



**Histology of uterine cervix.** A) Normal epithelium B) Dysplastic epithelium, a potentially premalignant change C) Cancer originating from the surface epithelium and eventually invading the underlying stroma, which is abundant in connective tissue and endocervical glands I) Different types of cells present in the epithelium of the uterine cervix II) Representation of the spatial arrangement of the cells in different layers in the epithelia of the uterine cervix and its comparison with different grades of premalignant lesion. (Adapted and modified from: Hans-Friedrich, 2007 and Strachan and Read, 2011)



**Risk factors associated with the development of the disease :**

- ❑ Human papillomavirus (HPV) infection
- ❑ Sexual activity at an early age
- ❑ Multiple sexual partners
- ❑ High Parity
- ❑ Dietary factors and addiction
- ❑ Compromised immune system
- ❑ Other Sexually transmitted disease (STD)

#### HPV-TYPES

**LOW RISK – (6, 11, 40, 42, 43 & 44)**

**INTERMEDIATE RISK – (31, 33, 39, 52 & 58)**

**HIGH RISK – (16, 18, 45 & 46)**

**7.9%** of women in the general population


**~99%** of invasive cervical cancers are positive for HPV

HPV contains a double stranded closed circular DNA genome of ~8kbp which is organized as –

**EARLY** genes

**LATE** genes

**UPSTREAM REGULATORY REGION (URR)**



- Prof. Harald zur Hausen was awarded Nobel Prize (in Physiology or Medicine) in the year 2008 for the discovery that HPV is the causal agent for uterine cervix cancer
- Prof. Hausen also emphasized the role of cellular factors in the HPV-induced transformation process

Albeit, human papillomavirus is widely known to be one of the major causes of the development of uterine cervix malignancy, the host plays potent role in the manifestation of the tumorigenic outgrowth.


This can be better exemplified by a very old hypothesis, dating back to 1967, embodied by Dr. Clyde E. Martin: “An infectious agent which is necessary although insufficient condition for the occurrence of the cancer”.



# Why does the virus invade only the epithelia ?

The discovery of an octamer sequence – “**ATGCAATT**”, in the region of the URR of HPV-16 and HPV-18 answered the question

- ❑ *BRN3A* silencing in HPV-positive cells, results in
  - ✓ Decreased cellular growth rate,
  - ✓ Reduced ability to form tumours and
  - ✓ (Most importantly) lowered the HPV-E6 expression
- ❑ *BRN3A* exhibits multiple folds overexpression in grade-3 of neoplasia as compared to that observed in the normal cervix



# Introduction of BRN3A/ Brn3a

- ❑ Apart from its prominent role in cancer of the uterine cervix, BRN3A is also associated with other human disorders, like:
  - ❖ Neuroendocrine tumour
  - ❖ Autoimmune disorder
  - ❖ Acute myeloid leukemia and cancer of the prostate gland and ovary
- ❑ Brn3a was initially identified to be a neuronal transcription factor, responsible for their survival and differentiation during the neuronal development
- ❑ Brn3a performs its anti-apoptotic functions in the neurons by regulating certain target genes like, Bcl-2, Bax, Noxa, etc.
- ❑ BRN3A is a homeodomain transcription factor. It is a member of the POU (Pit-1, Oct-1/2 & unc-86) family of transcription factors




## Objectives of the study

- ❖ **Exploration of the transcription factor, BRN3A, expression and regulation in cancer of the uterine cervix**
- ❖ **Identification of the BRN3A interacting partners in cancer of uterine cervix in order to decipher the molecular mechanism exerted by BRN3A in uterine cervix tumorigenicity**



# Differential expression of BRN3A in different stages of dysplasia of the uterine cervix




As dysplastic changes progress from the milder form to the severe ones extending to the carcinoma stage, the staining intensifies and the protein gets localized all over the cervix

**BRN3A expression directly correlates with the staging of the neoplastic growth in the uterine cervix and thus the expression possess histological significance**




**How is the oncoprotein, BRN3A, regulated in the  
uterine cervix?**

Elucidation of the pathway/s involved in the regulation of BRN3A in the uterine cervix



**“BRN3A is not suppressed” even on elevating and activating the endogenous HIPK2 through chemotherapeutic treatment in cervical cancer cells**




**“Autoregulation” appears to be the dominant regulatory mechanism of BRN3A in the uterine cervix**




**Unaltered BRN3A might be responsible for chemoresistance in cervical cancer cells**



Does any other transcription factor influence *BRN3A*?



Genotype of BRN3A (Enhancer)	Control (in %)	Case (in %)	P (OR (95% CI))
A/A	88.9	61.1	-
A/G	9.3	33.3	0.0098*
G/G	1.8	5.6	0.2953




Increase in luciferase activity in g.60163379 A>G variant in progesterone dependent manner

**How does BRN3A exert the tumourogenic activity?**



- ❖ p73 is a member of the p53-family of proteins
- ❖ E6 protein of HPV physically interacts with p53 and subsequently directs it towards proteolysis, but the same E6 is unable to interact with p73
- ❖ c-Jun NH<sub>2</sub>-terminal kinase (JNK) is a member of the mitogen-activated protein kinase (MAPK) family
- ❖ It is also known as stress-activated protein kinase (SAPK) as the kinase gets activated when the cell experiences genotoxic stress
- ❖ Brn3a has been observed to modulate the function of p73 in ND7 neuron derived cell line
- ❖ JNK under the influence of oncoproteins also signals the transformation of cells


**Does p73 and JNK get associated with the oncoprotein, BRN3A, in uterine cervix cancer?**




**Co-localization of BRN3A and p53-family member, p73, in SiHa cells**




Cisplatin: 0  $\mu\text{g ml}^{-1}$



Cisplatin: 5  $\mu\text{g ml}^{-1}$



Co-immunoprecipitation with anti-BRN3A antibody for the precipitation of p73 and activated-JNK in uterine cervix cancer cells for knowing their association




The oncogenicity of BRN3A in uterine cervix cancer cells is through its association with p73 and activated-JNK



**Are there any more interacting  
partners of BRN3A present in the  
uterine cervix?**



# Identification of BRN3A interacting partners in the uterine cervix

Cancerous cervix lysate	-	+	-	+	+
Normal cervix lysate	+	-	+	-	-
GST+Brn3a	+	+	-	-	-
GST	-	-	+	+	-
Bead	+	+	+	+	-



Different interactors of BRN3A were isolated from the nuclear extract of normal and cancerous uterine cervix through GST pull-down assay. The interacting partners of BRN3A were then separated in an SDS-PAGE. The peptides were extracted through in-gel trypsin digestion and processed for MALDI-TOF





❑ Plausible interacting partners of homeodomain transcription factor, BRN3A, in the uterine cervix cells:

1. Synaptonemal complex protein 2
2. POU domain, class 4, transcription factor 2 (**BRN3B**)
3. **Cervical cancer suppressor gene-4 protein (MAPKK kinase)**
4. Spermatogenesis-associated protein 24
5. **Mitogen-activated protein kinase 10 isoform 4 (JNK3)**
6. **AML 1**
7. Mutant Pax6
8. Friend leukemia integration 1 transcription factor isoform 2 (**Proto-oncogene Fli-1**)
9. Histone H1.3 Friend leukemia integration 1 transcription factor isoform 2



# Summary of the results

- ❑ Preliminary investigation of the oncoprotein, BRN3A, reveals that it is mostly active in the uterine cervix for the trans-activation of its target genes

- ❑ In the uterine cervix, there is no physical association of homeodomain transcription factor, BRN3A, and co-repressor of homeodomain proteins, HIPK2

The lack of interaction between homeodomain transcription factor, BRN3A, and co-repressor of homeodomain proteins, HIPK2, is one of the conceivable reason for the unaltered status of BRN3A expression under the condition of elevated HIPK2 in uterine cervix cancer cells

- ❑ BRN3A binds to its own enhancer *in vivo* for the autoregulation, with the consequence of upholding its steady state in genotoxically stressed uterine cervix cancer cells

The insensitivity of the oncoprotein, BRN3A, to the chemotherapeutic treatment suggests that it is one of the plausible mechanisms of chemoresistance

- ❑ Interestingly, the 60163379 A>G may be argued to be decreasing the risk of high-risk HPV-induced cancer of the uterine cervix as well

- ❑ Amongst the intricate associations of cellular factors in the tumorigenicity of uterine cervix cells, two vital cellular regulators, p73 and JNK has been observed to be associated with BRN3A

These associations may be contemplated in assisting BRN3A for the immortalization and transformation processes in uterine cervix cells

## Conclusion

**The propensity of development of uterine cervix tumour and subsequently into malignant lesions is guided by the homeodomain transcription factor, BRN3A**

**This host cellular factor not only facilitates high-risk HPV infection in the uterine cervix, but this study elaborates the projected risk and role of BRN3A in development of uterine cervix cancer in general**

BRN3A may be entitled as the key component in uterine cervix cancer  
& specifically in HPV-induced CaCx



**“Prevention is better than cure” — possible in cancer !!!**

# Scientific Credential

## Scientific Score

- **h-index** — 8
- **i-10 index** — 8

## Manuscript (Under-submission &/ or -preparation)

- **BP Das Purkayastha\***, A Prakash\*, *et.al.*, (**Under review**). Identification of a novel variation in the sensory enhancer of oncogene, BRN3A, in the uterine cervix (\***contributed equally**)
- **BP Das Purkayastha\***, A Chelluboyina\*, *et.al.*, (**Under preparation**). Identification of novel disease susceptibility genomic factors in familial syndrome of esophageal adenocarcinoma and Barrett esophagus (\***contributed equally**)
- A Baru, S Sharma, **BP Das Purkayastha**, *et.al.*, (**Under review**). AXTEX-4D™: A novel 3D *ex vivo* platform for preclinical investigations of immunotherapy agents
- A Baru, S Mazumdar, P Kundu, S Sharma, **BP Das Purkayastha**, *et.al.*, (**Under review**). Recapitulating tumor microenvironment using preclinical 3D tissueoids model for accelerating cancer research and drug screening
- S Mazumdar, R rastogi, A Sundale, K Arora, N M Arora, **BP Das Purkayastha**, *et.al.*, (**Under review**). PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2

## Peer-reviewed Prime Research

- **BP Das Purkayastha**, ER Chan, D Ravillah, L Ravi, R Gupta, MI Canto, JS Wang, NJ Shaheen, JE Willis, A Chak, V Varadan, K Guda (2020). Genome-Scale Analysis Identifies Novel Transcript-Variants in Esophageal Adenocarcinoma, *Cellular and Molecular Gastroenterology and Hepatology* (**IF-9.2**), 10 (3), 652-654, e17. (<https://pubmed.ncbi.nlm.nih.gov/32344180>)
- G Weber\*, **B Purkayastha\***, L Ren, S Pushpakumar and U Sen (2018). Hypertension exaggerates renovascular resistance via miR-122-associated stress response in aging, *Journal of Hypertension* (**IF-4.1**), 36(11), 2226-2236. (\***contributed equally**). (<https://pubmed.ncbi.nlm.nih.gov/30256768/>)
- RK Sharma, ZS Cheda, **BP Das Purkayastha**, *et.al.*, (2016). A spontaneous metastasis model reveals the significance of claudin-9 overexpression in lung cancer metastasis, *Clinical & Experimental Metastasis*, (**IF-3.1**), 33(3), 263-275. (<https://pubmed.ncbi.nlm.nih.gov/26669782>)
- **BP Das Purkayastha** and Jagat Kumar Roy, (2014). Cancer cell metabolism and developmental homeodomain/ POU domain transcription factors: A connecting link, *Cancer Letters* (**IF-7.4**), 356; 2A, 315-319. (<https://doi.org/10.1016/j.canlet.2014.05.015>)
- **BP Das Purkayastha** and Jagat Kumar Roy, (2011). Molecular analysis of oncogenicity of the transcription factor, BRN3A, in cervical cancer cells, *Journal of Cancer Research & Clinical Oncology* (**IF-3.6**), 137, 1859-1867. (<https://pubmed.ncbi.nlm.nih.gov/21928122>)



### **Significant Discovery**

- **Novel mRNA, Collagen type X alpha 1 chain var1 (COL10A1var1) mRNA** --- Submitted to the NCBI GenBank (Accession Number: MN308081) (<https://www.ncbi.nlm.nih.gov/nuccore/MN308081?report=GenBank>)
- **A single nucleotide variant in the regulatory region of BRN3A** --- Submitted to NCBI SNP database (dbSNP). (Accession Number.: ss289117722)

### **Manuscript from collaborative projects**

- NK Singh, BP Das Purkayastha, *et.al.*, (2012). *Journal of Applied Polymer Science* (IF-2.5), 127, 2465-2474. (<https://doi.org/10.1002/app.37954>)
- NK Singh, BP Das Purkayastha, *et.al.*, (2012). *Journal of Material Chemistry* (IF-11.3), 22, 17853-17863. <https://doi.org/10.1039/C2JM32340K>
- A Mishra, BP Das Purkayastha, *et.al.*, (2012). *Journal of Physical Chemistry C* (IF-4.2), 116, 2260–2270. (<https://doi.org/10.1021/jp210560s>)
- NK Singh, BP Das Purkayastha, *et.al.*, (2011). *Journal of Materials Chemistry* (IF-11.3), 21, 15919-15927. (<https://pubs.rsc.org/en/content/articlelanding/2011/jm/cljm12427g>)

### **GRANT/ FELLOWSHIP/ AWARD**

- **DBT–Research Associateship in Biotechnology and Life Sciences – Indian Institute of Sciences (Bangalore, India) and Department of Biotechnology, Government of India, (New Delhi, India)** (Period: **2013-2014**) for the project entitled: Diagnosis of HPV infection in asymptomatic women of NE–India and development of a novel therapeutic approach for the control of HPV infection and subsequent tumorigenicity
- **Senior Scholarship by Lady Tata Memorial Trust, Mumbai, India** (Period: **2010–2012**) for the project entitled: Study of the regulation of BRN3A in cancer of the uterine cervix

### **MEMBERSHIP:**

- Life Member, Indian Society of Cell Biology, INDIA
- Student Member, American Heart Association, USA
- Student Member, Indian Society of Human Genetics, INDIA

### **VOLUNTARY SERVICES & EXTRA-CURRICULAR ACTIVITY:**

- Voluntarily judged scientific posters on October 11, 2016 in the scientific event, ‘Research over Louisville’ at University of Louisville (Kentucky), USA
- Voluntarily judged scientific posters on October 27, 2015 in the scientific event, ‘Research over Louisville’ at University of Louisville (Kentucky), USA
- Student Member of the NGO, ‘Environmental Society of North Assam’, Assam, INDIA

# Thank you

Please feel free to contact:



+91-7428775800



[bpdasp@gmail.com](mailto:bpdasp@gmail.com)



[bpdasp@gmail.com](mailto:bpdasp@gmail.com)




<https://www.linkedin.com/in/bp-das-p-02aa56a3>



# Research Activity

Academic research experience

January 2013 - December 2014



**Study on the transcription factor, BRN3A, in etiology of uterine cervix cancer**

Silchar (Assam), India

Academic research experience

March 2015 - February 2017



**Molecular mechanism of metastasis & chemoresistance in aggressive lung cancer**

Louisville (Kentucky), USA

Academic research experience

February 2017 - January 2020



**Understand the molecular genetics involved in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC)**

Cleveland (Ohio), USA

Industrial research experience

January 2020 - May 2021



**Development of 3-D mammalian cell-culture model using a patented technology**

Gurgaon (HR), INDIA